Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:EU GVP: Module XVI EMA/204715/2012 Rev. 3 (2024): Difference between revisions

From GxPlex

Jump to: navigation, search
gxplex>GxPlexBot
Import from GxPlex Excel
Migrate to Template:DocumentData for PageForms (GxPlexBot)
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<noinclude>{{#set:
{{DocumentData
|DocReference=EU  GVP: Module XVI
EMA/204715/2012  Rev. 3 (2024)
|DocValidityArea=EU
|DocScopes=G
|DocName=GVP: Module XVI
EMA/204715/2012
|DocVersion=Rev. 3 (2024)
|DocStatus=Current
|DocType=Official guideline
|DocLanguage=EN
|DocDescription=Guideline on good pharmacovigilance practices (GVP)
Module XVI – Risk minimisation measures (Rev 3)
 
(Including NIS)
|DocRestricted=No
|DocSubmittedBy=Florian Adragna
|DocContributors=
}}</noinclude>
 
{{DocumentBox
|reference=EU  GVP: Module XVI
|reference=EU  GVP: Module XVI
EMA/204715/2012  Rev. 3 (2024)
EMA/204715/2012  Rev. 3 (2024)

Latest revision as of 12:54, 16 July 2026


Document information
Reference EU GVP: Module XVI

EMA/204715/2012 Rev. 3 (2024)

Validity area EU
Scope(s) G
Document name GVP: Module XVI

EMA/204715/2012

Version / Revision Rev. 3 (2024)
Status Current
Document type Official guideline
Language(s) EN
Description Guideline on good pharmacovigilance practices (GVP)

Module XVI – Risk minimisation measures (Rev 3)

(Including NIS)

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors

References

No references yet.